Pfizer Inc. has synthesized substituted fused heteroaryl lactam compounds acting as dual calcitonin (CALCR; CT-R)/amylin receptor agonists potentially useful for the treatment of obesity and type 2 diabetes.

Sironax Ltd. has disclosed new NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors potentially useful for the treatment of Parkinson’s disease, multiple sclerosis, traumatic brain injury, diabetic neuropathy, Alzheimer’s disease, Huntington’s disease, hereditary neuropathies, and stroke.

Several Sanofi SA patents divulge new mitogen-activated protein kinase 7 (MAPK7; ERK5) inhibitors potentially useful for the treatment of cancer.

Vivozon Inc. has identified new heterocyclic dual 5-HT2A/dopamine D2 receptor antagonists potentially useful for the treatment of schizophrenia.

Gilead Sciences Inc. has reported new protein arginine N-methyltransferase 5 (PRMT5) inhibitors potentially useful for the treatment of cancer.

Phrontline Biopharma (Hangzhou) Co. Ltd. has prepared and tested bispecific antibody-drug conjugates (bsADCs) comprising a bispecific antibody targeting B7 homolog 3 (B7-H3; CD276) and EGFR (HER1; erbB1) linked to a cytotoxic drug. They are described as potentially useful for the treatment of cancer.

Shanghai Allink Biotherapeutics Co. Ltd. has discovered new bispecific antibody-drug conjugates comprising a bispecific monoclonal antibody linked to a cytotoxic drug potentially useful for the treatment of cancer.

Dewpoint Therapeutics Inc. has patented new β-catenin (CTNNB1) condensate modulators potentially useful for the treatment of cancer.

Aeovian Pharmaceuticals Inc. has divulged new ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors potentially useful for the treatment of neurodegeneration, inflammation, fibrosis, systemic scleroderma, vascular disorders, Duchenne muscular dystrophy, liver and metabolic diseases, among others.

Foghorn Therapeutics Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding agent coupled to a histone acetyltransferase p300 (EP300)-targeting moiety. As such, they are described as EP300 degradation inducers potentially useful for the treatment of cancer.